CHP
SNDX icon

Cable Hill Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Cable Hill Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10
Closed -$106 – 946
2017
Q4 		$0 Sell
10
-990
-99% -$9.8K ﹤0.01% 1008
2017
Q3 		$12K Buy
+1,000
New +$12.3K 0.01% 528

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cable Hill Partners's SNDX Position: Q1 2018 in Review

Cable Hill Partners sold out of Syndax Pharmaceuticals (SNDX) in Q1 2018, closing a stake of 10 shares — an estimated $106 sold.

Cable Hill Partners first reported a position in SNDX in Q3 2017 and held it in 2 quarters. The position peaked at $12K in Q3 2017. 72 funds tracked by Wall St. Rank hold SNDX as of Q1 2018.

  • Cable Hill Partners reported no remaining Syndax Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 10 Syndax Pharmaceuticals shares in Q1 2018, an estimated $106.
  • Cable Hill Partners first reported a position in Syndax Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Cable Hill Partners's Syndax Pharmaceuticals position peaked at $12K in Q3 2017.
  • 72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.